首页> 外文期刊>World Journal of Gastroenterology >Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment
【24h】

Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment

机译:干扰素α-2b治疗后慢性乙型肝炎患者血清和组织学变化

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: Chronic hepatitis B is a serious health problem. Interferon has long been used to treat Chronic hepatitis B. To evaluate the effects of interferon on chronic hepatitis B better, we designed the study to investigate the changes in sera and liver histology of patients with chronic hepatitis B after interferon alpha-2b treatment. METHODS: Twenty-four patients with chronic hepatitis B were enrolled in this study. They all received interferon alpha-2b treatment as following: 3 million units, i.m.. t.i.w., for 18 weeks. Sera of all patients were obtained respectively for evaluation of ALT, HBsAg, HBcAg, HBeAg, HBV DNA and TIMP-1 before and after interferon treatment, also a liver biopsy pre- and post-treatment was performed for comparison of HAI, HBsAg, HBcAg, HBeAg, TIMP-1 and activated HSC in the liver tissue. RESULTS: Patients who had normalization of serum ALT and seroconversion of HBeAg and/or HBV DNA (blot hybridization) after treatment were defined as responders. The response rate in this study group was 37.5% (7/24). Compared to pretreatment, the serum HBV DNA and TIMP-1 decreased significantly (P<0.05), so did the HAI, HBcAg, HBeAg, TIMP-1 and activated HSC (P<0.05). CONCLUSION: The significant decrease in HBV DNA in sera, the seroconversion of HBeAg, and the decrease of viral expression in liver indicated that interferon alpha-2b treatment can inhibit viral replication. The normalization of ALT in sera and the improvement of HAI in liver showed that interferon alpha-2b can improve the liver histology of patients with chronic hepatitis B. At the same time, interferon alpha-2b treatment can reduce the TIMP-1 in serum and liver and decrease the number of activated HSC, which may ailievate or inhibit hepatic fibrosis. Although the response rate was unsatisfactory, interferon play a benefical role on patients with chronic hepatitis B in other respects. We still need further studies to improve the therapy effects.
机译:目的:慢性乙型肝炎是一个严重的健康问题。干扰素长期以来一直用于治疗慢性乙型肝炎。为了更好地评估干扰素对慢性乙型肝炎的影响,我们设计了这项研究,以研究干扰素α-2b治疗后慢性乙型肝炎患者的血清和肝脏组织学变化。方法:本研究纳入了24例慢性乙型肝炎患者。他们都接受了如下干扰素α-2b治疗:300万单位,即t.i.w.,持续18周。分别获得所有患者的血清以评估干扰素治疗前后的ALT,HBsAg,HBcAg,HBeAg,HBV DNA和TIMP-1,还进行了肝活检前后的比较,以比较HAI,HBsAg,HBcAg ,肝组织中的HBeAg,TIMP-1和活化的HSC。结果:治疗后血清ALT正常且HBeAg和/或HBV DNA发生血清转化(印迹杂交)的患者被定义为有反应者。该研究组的缓解率为37.5%(7/24)。与预处理相比,血清HBV DNA和TIMP-1显着降低(P <0.05),HAI,HBcAg,HBeAg,TIMP-1和活化的HSC也明显降低(P <0.05)。结论:血清HBV DNA的显着降低,HBeAg的血清转化和肝脏中病毒表达的降低表明干扰素α-2b治疗可抑制病毒复制。血清ALT的正常化和肝HAI的改善表明,干扰素α-2b可以改善慢性乙型肝炎患者的肝脏组织学。同时,干扰素α-2b的治疗可以降低血清中的TIMP-1和肝脏并减少激活的HSC数量,这可能会减轻或抑制肝纤维化。尽管反应率不能令人满意,但是干扰素在其他方面对慢性乙型肝炎患者起着有益的作用。我们仍然需要进一步的研究来改善治疗效果。

著录项

  • 来源
    《World Journal of Gastroenterology》 |2003年第1期|p.117-121|共5页
  • 作者

    Hong-Lei Han; Zhen-Wei Lang;

  • 作者单位

    Department of Pathology, Beijing Youan Hospital, Beijing 100054, Beijng City, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

  • 入库时间 2022-08-17 23:37:38

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号